




# Programa

JUEVES | 3 DE MARZO DE 2022

7:50 - 8:50			REGISTRO E INSCRIPCIONES
09:00	<b>INAUGURACIÓN</b>		<b>Maestra de Ceremonias:</b> Dra. Eva Ruvalcaba Limón
09:20	<b>TRIPLE NEGATIVE</b>	GS1-01: KEYNOTE-522 Study of Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy, Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC: Event-Free Survival Sensitivity and Subgroup Analyses	Dr. Santiago Cano Canela
09:35		GS1-02: Efficacy of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy by PD-L1 Combined positive score 1-9, 10-19 and >20 for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer: KEYNOTE 355 Subgroup Analysis	Dr. Hugo Millán Aguilar
09:50		G2-10: NIMBUS: A phase II study of Nivolumab plus Ipilimumab in metastatic Hipermutated HER2-Negative Breast Cancer	Dra. Perla Pérez Pérez
10:05		GS4-09: Quality of Life Results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant Olaparib after (neo) adjuvant chemotherapy in patients with germline BRCA 1/2 mutations and high-risk HER-2 negative early breast cancer	Dr. Fernando Aldaco Sarvide
10:20	<b>Panel de Discusión</b>		<b>Coordinadora:</b> Dra. Guadalupe Cervantes Sánchez
10:40	<b>“Papel de la inmunoterapia en cáncer de mama triple negativo”</b>		Dr. Brizio Moreno Jaime Dra. Paula Cabrera Galeana
11:25 <b>RECESO</b>			
12:00	<b>De la evidencia científica a la experiencia en el mundo real: Manejo del CMm RH+ HER2-</b>		Dr. Andrés de Jesus Morán Mendoza
12:45	<b>LOCAL THERAPY</b>	GS4-03: Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer	Dra. Michelle Rojas Arellano
13:00		GS4-05: Preservation of axillary lymph nodes compared to complete dissection in T1-2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes: A multicenter randomized clinical trial. SINODAR-ONE	Dr. Felipe Villegas Carlos
13:15		ES8-2: Can Radiotherapy Replace Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy?	Dr. Azcary Vázquez Tinajero
13:30		ES8-3: Refining Axillary Management after Neoadjuvant Chemotherapy: What Does the Evidence Support?	Dr. Pabel Miranda Aguirre
13:45	<b>Panel de Discusión</b>		<b>Coordinador:</b> Dr. Gregorio Quintero Beuló
14:05 <b>CIERRE DEL DÍA</b>			



# Programa

VIERNES | 4 DE MARZO DE 2022

7:50 - 8:50			REGISTRO E INSCRIPCIONES
09:00	<b>PRESENTACIÓN DEL DÍA</b>		<b>Maestro de Ceremonias:</b> Dr. Pabel Miranda Aguirre
09:10	Imaging/Local Therapy	GS4-06: Estimation of Breast Cancer Overdiagnosis in a US Breast Screening Cohort	Dra. Daniela Martínez del Razo
09:25		MS2-01: The evolution of local Therapy in the genomic Era: Is Less (or More) axillary surgery Needed?	Dr. Jorge Enrique Monges Jones
09:40		<b>Panel de Discusión</b>	<b>Coordinador:</b> Dr. Juan Alberto Tenorio Torres
10:00		Experiencia Clínica en la UNEME Zacatecas con tratamientos para cáncer de mama.	Dr. Eduardo Bustos Balderas
10:30		DB1 PRO: One Week of whole breast radiotherapy is the new standard of care	Dr. Hugo Romero Anduaga
10:45		DB1 CON: Five Fraction Whole Breast Irradiation for Breast Conserving Therapy: NOT the Standard of Care	Dr. Emmanuel Sandoval Méndez
11:00		<b>Panel de Discusión</b>	<b>Coordinador:</b> Dr. Anselmo Vázquez Delgado
11:20	<b>“Las pacientes con CMM BRCA+: Actualidades de tratamiento”</b>		Dra. Cynthia Villarreal Garza
12:05 <b>RECESO</b>			
12:30	HER2 Positive	<b>“Trastuzumab Emtansina en el tratamiento del Cáncer de mama HER2 positivo con enfermedad residual en mama y/o ganglios PostNeoadyuvancia”</b>	Dra. Cynthia Villarreal Garza Dra. Nereida Esparza Arias
13:15		GS3-01: Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2+ Metastatic Breast Cancer: Subgroup Analyses From the Randomized Phase 3 Study DESTINY-Breast03	Dra. María Del Mar García Ortega
13:30		GS4-10: Neratinib + Fulvestrant + Trastuzumab for hormone-receptor positive, HER2-mutant metastatic breast cancer, and Neratinib + Trastuzumab for metastatic triple negative disease: latest update for the SUMMIT Trial	Dra. Lizeth Nava Flores
13:45		GS3-02: Updated overall survival results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer	Dr. Benito Sánchez Llamas
14:00			<b>Panel de Discusión</b>
14:20 <b>CIERRE DEL DÍA</b>			



# Programa

SÁBADO | 5 DE MARZO DE 2022

7:50 - 8:50		
09:00	<b>PRESENTACIÓN DEL DÍA</b>	<b>Maestra de Ceremonias:</b> Dra. Betsabé Hernández Hernández
09:10	GS2-04: Aromatasa Inhibitors vs Tamoxifen in Premenopausal women with ER+ early stage breast treated with ovarian suppression: A patient level Meta-Analysis of 7,030 women in four randomized trials	Dr. Luis Romero Robles
09:25	GS2-05: Randomized comparison of adjuvant Exemestane + ovarian function suppression (OFS) vs Tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials	Dra. Eva Ruvalcaba Limón
09:40	GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes, hormone receptor-positive (HR+) and HER2-negative breast cancer with recurrence score of 25 or less: SWOG S1007	Dr. Carlos Gómez Cuevas
09:55	<b>Panel de Discusión</b>	<b>Coordinadora:</b> Dra. Flavia Morales Vásquez
10:15	GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final protocol-planned analysis results form 5,761 patients in the randomized phase III PALLAS trial	Dra. Denisse Añorve Bailón
10:30	GS2-00: Correlative Analysis of Overall Survival by Intrinsic Subtype Across the MONALEESA-2,-3, and -7 Studies of Ribociclib + Endocrine Therapy in Patients With HR+/HER2- Advanced Breast Cancer	Dr. Lorben López Rodríguez
10:45	GS2-01: Overall Survival Subgroup Analysis by Metastatic Site From the Phase 3 MONALEESA-2 Study of First-Line Ribociclib + Letrozole in Postmenopausal Patients With HR+/HER2- Advanced Breast Cancer	Dra. Zuratzi Deneken Hernández
11:00	<b>Panel de Discusión</b>	<b>Coordinador:</b> Dr. Lorben López Rodríguez
11:20 <b>RECESO</b>		
11:40	GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial	Dra. Ana María Zempoalteca López
11:55	GS1-06: A Randomized Controlled Phase III trial of Entinostat, a Class I Selective Histone Deacetylase Inhibitor, in Combination with Exemestane in Patients with Hormone Receptor Positive Advanced Breast Cancer	Dr. Enrique Talamantes Gómez
12:10	GS3-10: Study of Samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer	Dra. Denisse Lee Cervantes
12:25	<b>Panel de Discusión</b>	<b>Coordinador:</b> Dr. Ricardo Villalobos Valencia
13:45 <b>CLAUSURA</b>		

Hormonal Receptor Positive

Hormonal Receptor Positive